aTYR PHARMA INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 |
| Research and development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M |
| Operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Pretax income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| Balance Sheet | |||||
| Cash and equivalents | $10.7M | $11.1M | $22.5M | $10.0M | $2.3M |
| Current assets | $80.2M | $82.0M | $103.0M | $80.9M | $113.6M |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
| Current liabilities | $15.1M | $15.0M | $16.4M | $13.9M | $6.0M |
| Stockholders' equity | $67.5M | $70.0M | $90.7M | $71.5M | $109.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Depreciation and amortization | $664,000 | $708,000 | $592,000 | $232,000 | $475,000 |
| Stock-based compensation | $5.0M | $3.0M | $2.6M | $2.2M | $1.6M |
| Capital expenditure | $77,000 | $65,000 | $4.2M | $1.6M | $192,000 |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 98.1M · Free float 95.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.